Ratings by BTIG (Robert Hazlett)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/24/2025 | Compass Pathways | CMPS | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2023 | Compass Pathways | CMPS | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2023 | Paratek Pharmaceuticals | PRTK | Maintain | Buy (N/A) |
|
Details | ||
| 3/7/2023 | CTI BioPharma | CTIC | Maintain | Buy (N/A) |
|
Details | ||
| 2/7/2023 | Lyra Therapeutics | LYRA | Maintain | Buy (N/A) |
|
Details | ||
| 11/7/2022 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 10/26/2022 | Aravive Inc. | ARAV | Maintain | Buy (N/A) |
|
Details | ||
| 10/5/2022 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 9/7/2022 | Eiger BioPharma | EIGR | Maintain | Buy (N/A) |
|
Details | ||
| 8/16/2022 | Homology Medicines | FIXX | Maintain | Buy (N/A) |
|
Details | ||
| 5/11/2022 | Lyra Therapeutics | LYRA | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2022 | Akebia Therapeutics | AKBA | Downgrade | Neutral (Buy) |
0.83 (1.24) |
49.4% | Details | |
| 3/18/2022 | Eiger BioPharma | EIGR | Maintain | Buy (N/A) |
|
Details | ||
| 3/14/2022 | Nektar Therapeutics | NKTR | Downgrade | Neutral (Buy) |
10.63 (1.17) |
-88.99% | Details | |
| 3/2/2022 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2022 | CTI BioPharma | CTIC | Maintain | Buy (N/A) |
|
Details | ||
| 2/23/2022 | Zosano Pharma | ZSAN | Downgrade | Neutral (Buy) |
0.22 (0.56) |
154.55% | Details | |
| 2/22/2022 | Homology Medicines | FIXX | Maintain | Buy (N/A) |
|
Details | ||
| 12/1/2021 | Redhill Biopharma | RDHL | Maintain | Buy (N/A) |
|
Details | ||
| 11/23/2021 | Aura Biosciences | AURA | New Coverage | Buy (N/A) |
19.63 (7.74) |
-60.57% | Details | |
| 11/8/2021 | Nektar Therapeutics | NKTR | Maintain | Buy (N/A) |
|
Details | ||
| 9/15/2021 | Redhill Biopharma | RDHL | Maintain | Buy (N/A) |
|
Details | ||
| 8/27/2021 | Redhill Biopharma | RDHL | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2021 | CTI BioPharma | CTIC | New Coverage | Buy (N/A) |
2.80 (9.09) |
224.64% | Details | |
| 6/25/2021 | Prothena Corp | PRTA | Maintain | Buy (N/A) |
|
Details | ||
| 5/27/2021 | Compass Pathways | CMPS | New Coverage | Buy (N/A) |
34.37 (13.62) |
-60.37% | Details | |
| 5/24/2021 | Verastem | VSTM | Upgrade | Buy (Neutral) |
3.19 (4.50) |
41.07% | Details | |
| 4/16/2021 | Tracon Pharmaceuticals | TCON | Upgrade | Buy (Neutral) |
7.81 (1.43) |
-81.69% | Details | |
| 2/24/2021 | MannKind | MNKD | Maintain | Buy (N/A) |
|
Details | ||
| 2/2/2021 | Matinas BioPharma Holdings Inc. | MTNB | Maintain | Buy (N/A) |
|
Details | ||
| 2/2/2021 | Prothena Corp | PRTA | Upgrade | Buy (Neutral) |
11.00 (9.69) |
-11.91% | Details | |
| 12/29/2020 | MannKind | MNKD | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2020 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2020 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 9/4/2020 | Akebia Therapeutics | AKBA | Maintain | Buy (N/A) |
|
Details | ||
| 5/26/2020 | Lyra Therapeutics | LYRA | New Coverage | Buy (N/A) |
14.43 (3.85) |
-73.32% | Details | |
| 5/6/2020 | Akebia Therapeutics | AKBA | Maintain | Buy (N/A) |
|
Details | ||
| 4/2/2020 | Eiger BioPharma | EIGR | Maintain | Buy (N/A) |
|
Details | ||
| 3/27/2020 | Zosano Pharma | ZSAN | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2020 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2020 | MannKind | MNKD | Maintain | Buy (N/A) |
|
Details | ||
| 11/1/2019 | Paratek Pharmaceuticals | PRTK | Maintain | Sell (N/A) |
|
Details | ||
| 6/20/2019 | Verastem | VSTM | Downgrade | Neutral (Buy) |
1.90 (3.19) |
67.89% | Details | |
| 6/14/2019 | Nektar Therapeutics | NKTR | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2019 | Matinas BioPharma Holdings Inc. | MTNB | New Coverage | Buy (N/A) |
0.92 (0.63) |
-31.52% | Details | |
| 5/14/2019 | MannKind | MNKD | New Coverage | Buy (N/A) |
1.25 (4.52) |
261.6% | Details | |
| 5/10/2019 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 4/12/2019 | Tracon Pharmaceuticals | TCON | Downgrade | Neutral (Buy) |
1.30 (1.43) |
10% | Details | |
| 2/21/2019 | Zosano Pharma | ZSAN | Maintain | Buy (N/A) |
|
Details | ||
| 2/12/2019 | Nektar Therapeutics | NKTR | Maintain | Buy (N/A) |
|
Details | ||
| 1/8/2019 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 12/26/2018 | Tracon Pharmaceuticals | TCON | Maintain | Buy (N/A) |
|
Details | ||
| 12/21/2018 | Forty Seven Inc. | FTSV | New Coverage | Buy (N/A) |
17.27 (95.51) |
453.04% | Details | |
| 12/19/2018 | Eiger BioPharma | EIGR | Maintain | Buy (N/A) |
|
Details | ||
| 9/26/2018 | Zosano Pharma | ZSAN | Maintain | Buy (N/A) |
|
Details | ||
| 9/25/2018 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details |
